世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

細胞・遺伝子治療薬送達デバイス市場-世界産業規模、シェア、動向、機会、予測、2018-2028年タイプ別(網膜下注入カニューレ、延長チューブ、静脈内カテーテル、滅菌インスリンシリンジ、プレフィルドシリンジ、輸液バッグ)、市販薬別(Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis)、投与経路別(経口、静脈内、眼、経皮、その他)、方法別(In Vitro v/s Ex Vivo)、地域別および競合別


Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Segmented By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags), By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis), By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others), By Method (In Vitro v/s Ex Vivo), By Region and Competition

細胞・遺伝子治療薬送達デバイスの世界市場は、予測期間2024-2028年に力強い成長を示すと予想される。この背景には、癌などの様々な慢性疾患の治療における細胞・遺伝子治療の利用が拡大していることがある。細胞... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
110 英語

 

サマリー

細胞・遺伝子治療薬送達デバイスの世界市場は、予測期間2024-2028年に力強い成長を示すと予想される。この背景には、癌などの様々な慢性疾患の治療における細胞・遺伝子治療の利用が拡大していることがある。細胞・遺伝子治療中の薬物投与量を効率的にモニタリングできるドラッグデリバリーデバイスに対する需要の高まりが、今後数年間の市場成長を支えるものと予想される。
細胞・遺伝子治療は、効率的な可能性を秘めた革新的な産業である。細胞・遺伝子治療には、ドナーから細胞、タンパク質、遺伝物質(DNA)を抽出し、それらを改変して高度に特異的で個別化された治療を提供することが含まれる。個別化医療の人気の高まりは、細胞・遺伝子治療の需要を大幅に増加させ、その結果、これらの治療を提供するために使用される装置の需要を生み出している。
効果的な投与は、標的部位における薬剤の生物学的利用能を最大化するのに役立ち、患者にとって便利であるため、今後数年間、細胞療法や遺伝子療法を含むさまざまな治療法の送達に使用される機器の成長を積極的に支援する。リングやパッチなどのバリエーションとして市場で入手可能な皮下インプラントのような新しい薬物送達システムは、予測期間における世界の細胞・遺伝子治療薬物送達デバイス市場の成長を後押しすると予想される。
慢性疾患の有病率の増加
人口の間で癌の有病率が憂慮すべき割合で増加しており、効果的な治療法の必要性が様々な細胞・遺伝子療法の開発につながった。細胞療法と遺伝子療法の開発は、それらを提供するために使用されるさまざまなデバイスの需要の増加につながり、それによって世界の細胞療法と遺伝子療法薬物送達デバイスの成長を推進している。Globocan 2020によると、世界中で新たに報告された癌の症例は約19,292,789件である。そのうち10,065,305人が男性で、肺がん、前立腺がん、大腸がん、胃がん、肝臓がんで占められている。同様に、女性で報告された新規がん症例数は約9,227,484例で、乳がん、大腸がん、肺がん、子宮頸がん、甲状腺がんが最も多い。
細胞・遺伝子治療と臨床試験に関するFDA承認の増加
2017年に最初の治療法が承認され、細胞療法と遺伝子療法は投資の世界では比較的新しいものである。Cell and Gene Journalによると、FDAが承認した22の細胞療法と遺伝子療法のうち、14は臍帯血ベースの治療法である。残りの承認は、2つの遺伝子療法、7つの細胞療法、5つの改変細胞療法である。また、承認された340の生物製剤のうち、細胞・遺伝子治療は全体のわずか7%である。また、2021年にFDAが承認した50以上の医薬品のうち、細胞・遺伝子治療はわずか2つである。2021年に承認された医薬品全体に占める割合は少ないが、承認された細胞・遺伝子治療薬が10%増加したことを反映しており、医学の発展における目覚ましい一歩である。このように、より優れたドラッグデリバリーデバイスを提供する最新の発売に対するFDAの承認数の増加は、細胞および遺伝子療法を提供するために使用されるデバイスの開発のための様々な企業の間で人気を集めている。このことは、今後数年間、世界の細胞・遺伝子治療薬物送達装置市場の成長を後押しすると予想される。
細胞・遺伝子治療市場への投資と資金調達の増加
細胞治療・遺伝子治療企業は、民間および公的投資による優れた金額と比率を得ている。治療法が確立されていない疾患や慢性疾患をターゲットとする新規細胞・遺伝子治療の保証は、民間投資、新規株式公開、企業からの多額の資金流入につながっている。ライフ・サイエンスへの民間投資の増加に伴い、細胞治療と遺伝子治療への投資も急増している。Cell and Gene Journal誌によると、2010年から2021年にかけての投資成長率は、遺伝子治療が59%であるのに対し、細胞治療は63%であり、これはより高い成長率であると同時に、予測期間中に世界の細胞・遺伝子治療薬物送達デバイス市場の成長を後押しする重要な役割をもたらすと予想されている。
また、いくつかの国の様々な政府は、患者や医師の間でデバイスに関する認識を高めるプロセスを支援しており、それによって細胞&遺伝子治療薬物送達デバイスの世界市場の成長をサポートしています。
市場セグメンテーション
細胞・遺伝子治療薬物送達デバイスの世界市場は、タイプ、製品化された薬剤、投与経路、方法、地域によって細分化される。タイプ別では、網膜下注入カニューレ、延長チューブ、静脈内カテーテル、滅菌インスリン注射器、プレフィルドシリンジ、輸液バッグに細分化される。商品化された薬剤に基づき、市場はさらにLuxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelisに細分化される。投与経路によって、市場はさらに経口、静脈内、眼、経皮、その他に区分される。投与方法の種類によって、市場は体外と生体外に区分される。地域別では、北米、欧州、アジア太平洋、南米、中東・アフリカに分布する。
市場プレイヤー
Becton, Dickinson, and Company、Novartis AG、Amgen Inc.、Kite Pharma, Inc.、Pfizer, Inc.、Bausch & Lomb Incorporated、Bluebird bio, Inc.、Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)、Dendreon Pharmaceuticals LLC.、Helixmith Co、Ltd.(ViroMed社)、Orchard Therapeutics plc、Renova Therapeutics、Spark Therapeutics, Inc.、uniQure N.V.、Vericel Corporationなどが、世界の細胞・遺伝子治療薬物送達装置市場で事業を展開する大手企業である。

レポートの範囲
本レポートでは、細胞・遺伝子治療薬物送達デバイスの世界市場を、業界動向に加えて、以下のカテゴリーに分類しています:
- 細胞・遺伝子治療薬物送達デバイス市場、タイプ別
o 網膜下注入カニューレ
o 延長チューブ
o 静脈カテーテル
o 滅菌インスリンシリンジ
o プレフィルドシリンジ
o 輸液バッグ
- 細胞・遺伝子治療薬送達デバイス市場、市販薬別
o ラクストゥーナ
o キムリア
o イエスカルタ
o ゾルゲンマ
o プロベンジ
o ストリムベリス
- 細胞・遺伝子治療薬物送達デバイス市場、投与経路別
o 経口
o 静注
o 眼
o 経皮
o その他
- 細胞・遺伝子治療薬物送達デバイス市場、方法別
o 体外
生体外
- 細胞・遺伝子治療薬物送達デバイス市場:地域別
北米
 米国
 カナダ
 メキシコ
欧州
 ドイツ
 フランス
 イギリス
 イタリア
 スペイン
o アジア太平洋
 中国
 日本
 インド
 韓国
 オーストラリア
中東・アフリカ
 南アフリカ
 サウジアラビア
 アラブ首長国連邦
o 南米
 ブラジル
 アルゼンチン
 コロンビア
競争状況
企業プロフィール:世界の細胞・遺伝子治療薬送達デバイス市場に参入している主要企業の詳細分析。
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
6.2.4. By Method (In Vitro v/s Ex Vivo)
6.2.5. By Company (2022)
6.2.6. By Region
6.3. Market Map
6.3.1. By Type
6.3.2. By Commercialized Drugs
6.3.3. By Route of Administration
6.3.4. By Method
6.3.5. By Region
7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
7.2.4. By Method (In Vitro v/s Ex Vivo)
7.2.5. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Commercialized Drugs
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Method
7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Commercialized Drugs
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Method
7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Commercialized Drugs
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Method
7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Commercialized Drugs
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Method
7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Commercialized Drugs
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Method
8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
8.2.4. By Method (In Vitro v/s Ex Vivo)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Commercialized Drugs
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Method
8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Commercialized Drugs
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Method
8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Commercialized Drugs
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Method
8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Commercialized Drugs
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Method
8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Commercialized Drugs
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Method
9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
9.2.4. By Method (In Vitro v/s Ex Vivo)
9.2.5. By Country
9.3. North America: Country Analysis
9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Commercialized Drugs
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Method
9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Commercialized Drugs
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Method
9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Commercialized Drugs
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Method
10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
10.2.4. By Method (In Vitro v/s Ex Vivo)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Commercialized Drugs
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Method
10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Commercialized Drugs
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Method
10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Commercialized Drugs
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Method
11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
11.2.4. By Method (In Vitro v/s Ex Vivo)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Commercialized Drugs
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Method
11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Commercialized Drugs
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Method
11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Commercialized Drugs
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Method
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Competitive Landscape
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As Reported)
14.5. Recent Developments
14.6. SWOT Analysis
14.6.1. Becton, Dickinson, and Company
14.6.2. Novartis AG
14.6.3. Amgen Inc.
14.6.4. Kite Pharma, Inc.
14.6.5. Pfizer, Inc.
14.6.6. Bausch & Lomb Incorporated
14.6.7. Bluebird bio, Inc.
14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
14.6.9. Dendreon Pharmaceuticals LLC.
14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd)
15. Strategic Recommendations

 

ページTOPに戻る


 

Summary

Global Cell & Gene Therapy Drug Delivery Devices market is expected to show robust growth in the forecast period, 2024-2028. This can be attributed to the growing use of cell and gene therapy for the treatment of various chronic diseases such as cancer. The increasing demand for drug delivery devices that are efficient in monitoring drug dosage during cell and gene therapies is expected to support market growth in the coming years.
Cell and Gene Therapy is a transformative industry that is emerging with efficient potential. Cell and Gene therapy includes the extraction of cells, proteins, or genetic material (DNA) from the Donor and altering them to provide highly specific and personalized therapy. The growing popularity of personalized medicine has significantly increased the demand for cell and gene therapies, thereby creating the demand for devices used to deliver these therapies.
The effective dosages help in maximizing the bioavailability of the drug at the target sites, making it convenient for the patients and thereby actively supporting the growth of devices used for delivering different therapies, including cell and gene therapies, in the coming years. Novel drug delivery systems like subdermal implants available in the market as variants such as rings and patches are anticipated to boost the global cell & gene therapy drug delivery devices market growth in the forecast period.
Increasing Prevalence of Chronic Diseases
The growing prevalence of cancer among the population at an alarming rate and the requirement for an effective treatment has led to the development of various cell and gene therapies. The development of cell and gene therapies has led to an increase in demand for different devices used to deliver them, thereby driving the growth of global cell and gene therapy drug delivery devices. According to the Globocan 2020, there are around 19,292,789 new cases of cancer reported among the population across the globe. Out of these, 10,065,305 new cancer cases were reported among males, and the most common type of cancer among them was Lung, Prostate, Colorectum, Stomach, and Liver cancer. Similarly, the number of new cancer cases reported in the female population was around 9,227,484, with breast cancer, colorectum cancer, lung cancer, cervix uteri, and thyroid cancer being the most prevalent ones.
A growing number of FDA approvals regarding Cell and Gene Therapies & Clinical Trials
With the first therapy approved in 2017, Cell therapies & Gene therapies are relatively new to the world for investments. According to the Cell and Gene Journal, out of 22 cell and gene therapies approved by the FDA, 14 are cord blood-based treatments. The remaining approvals include two gene therapies, seven cell therapies, and five modified cell therapies. Also, in total, cell & gene therapies account for just seven percent (7%) of the total 340 approved biologics. Also, of the over 50 total drugs approved by the FDA in 2021, only 2 were cell or gene therapies. Though it’s a small amount of the total approved drugs in 2021, it reflects that the approved cell and gene therapies grew by 10%, which is a remarkable step in the development of medicine. Thus, the growing number of FDA approvals for the latest launches providing better drug delivery devices are gaining popularity among various companies for the development of devices used for delivering cell and gene therapies. This, in turn, is expected to bolster the growth of global cell & gene therapy drug delivery devices market in the coming years.
Increased Investment and Funding in the Cell and Gene Therapy Market
The Cell therapy & Gene therapy companies are getting an excellent amount & proportion of private and public investment. The assurance of novel cell and gene therapies which are targeting poorly treated diseases and chronic conditions has led to substantial capital flowing from private investments, initial public offerings, and corporates. With the growing private investment in life sciences, the rapid growth in investment in cell therapy and gene therapy is accountable. According to the Cell and Gene Journal, for gene therapy, the investment growth rate from 2010 to 2021 has risen to 59%, whereas for cell therapy, the investment rate has grown to 63%, which is accountable on a higher note and also anticipated for bringing a significant role in boosting the Global Cell & Gene Therapy Drug Delivery Devices Market growth during the forecast period.
Also, the various Government of several countries is aiding the process of increasing awareness about the devices among patients and doctors, thereby supporting the Global Cell & Gene Therapy Drug Delivery Devices market growth.
Market Segmentation
Global Cell & Gene Therapy Drug Delivery Devices Market can be segmented by type, commercialized drugs, route of administration, method, and region. Based on type, the market is fragmented into subretinal injection cannulas, extension tubes, intravenous catheters, sterile insulin syringes, prefilled syringe, and infusion bags. Based on the Commercialized Drugs, the market is further segmented into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis. Depending on the Route of Administration, the market is further segmented into Oral, Intravenous, Ocular, Transdermal, and Others. Based on the type of method, the market can be segmented into In Vitro and Ex Vivo. Based on the regional segmentation, the market is distributed among North America, Europe, Asia- Pacific, South America, and Middle East and Africa.
Market Players
Becton, Dickinson, and Company, Novartis AG, Amgen Inc., Kite Pharma, Inc., Pfizer, Inc., Bausch & Lomb Incorporated, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Orchard Therapeutics plc, Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., Vericel Corporation, are some of the leading players operating in the global cell & gene therapy drug delivery devices market.

Report Scope:
In this report, global cell & gene therapy drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Cell & Gene Therapy Drug Delivery Devices Market, By Type:
o Subretinal Injection Cannula
o Extension Tube
o Intravenous Catheter
o Sterile Insulin Syringe
o Prefilled Syringe
o Infusion Bags
• Cell & Gene Therapy Drug Delivery Devices Market, By Commercialized Drugs:
o Luxturna
o Kymriah
o Yescarta
o Zolgensma
o Provenge
o Strimvelis
• Cell & Gene Therapy Drug Delivery Devices Market, By Route of Administration:
o Oral
o Intravenous
o Ocular
o Transdermal
o Others
• Cell & Gene Therapy Drug Delivery Devices Market, By Method:
o In Vitro
o Ex Vivo
• Cell & Gene Therapy Drug Delivery Devices Market, By Region:
o North America
 United States
 Canada
 Mexico
o Europe
 Germany
 France
 United Kingdom
 Italy
 Spain
o Asia-Pacific
 China
 Japan
 India
 South Korea
 Australia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
o South America
 Brazil
 Argentina
 Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global Cell & Gene Therapy Drug Delivery Devices market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
6.2.4. By Method (In Vitro v/s Ex Vivo)
6.2.5. By Company (2022)
6.2.6. By Region
6.3. Market Map
6.3.1. By Type
6.3.2. By Commercialized Drugs
6.3.3. By Route of Administration
6.3.4. By Method
6.3.5. By Region
7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
7.2.4. By Method (In Vitro v/s Ex Vivo)
7.2.5. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Commercialized Drugs
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Method
7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Commercialized Drugs
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Method
7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Commercialized Drugs
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Method
7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Commercialized Drugs
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Method
7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Commercialized Drugs
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Method
8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
8.2.4. By Method (In Vitro v/s Ex Vivo)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Commercialized Drugs
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Method
8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Commercialized Drugs
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Method
8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Commercialized Drugs
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Method
8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Commercialized Drugs
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Method
8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Commercialized Drugs
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Method
9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
9.2.4. By Method (In Vitro v/s Ex Vivo)
9.2.5. By Country
9.3. North America: Country Analysis
9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Commercialized Drugs
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Method
9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Commercialized Drugs
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Method
9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Commercialized Drugs
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Method
10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
10.2.4. By Method (In Vitro v/s Ex Vivo)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Commercialized Drugs
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Method
10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Commercialized Drugs
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Method
10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Commercialized Drugs
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Method
11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
11.2.4. By Method (In Vitro v/s Ex Vivo)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Commercialized Drugs
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Method
11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Commercialized Drugs
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Method
11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Commercialized Drugs
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Method
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Competitive Landscape
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As Reported)
14.5. Recent Developments
14.6. SWOT Analysis
14.6.1. Becton, Dickinson, and Company
14.6.2. Novartis AG
14.6.3. Amgen Inc.
14.6.4. Kite Pharma, Inc.
14.6.5. Pfizer, Inc.
14.6.6. Bausch & Lomb Incorporated
14.6.7. Bluebird bio, Inc.
14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
14.6.9. Dendreon Pharmaceuticals LLC.
14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd)
15. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

TechSci Research社の世界/地域別市場調査分野での最新刊レポート

本レポートと同じKEY WORD(devices)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る